Effectiveness and Patient Satisfaction With Zastaprazan in Real-World Practice: A Large-Scale Prospective Observational Study
4 affiliations
- 1Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine Seoul Korea
- 2JEIL Pharmaceutical Co, Ltd Seoul Korea
- 3Digestive Disease Research Institute, Wonkwang University School of Medicine Iksan Korea
- 4Kim’s GutEase Internal Medicine Gunpo Korea
Abstract
Background/Aims: Gastroesophageal reflux disease (GERD) remains a prevalent condition with unmet therapeutic needs. Zastaprazan is a novel potassium-competitive acid blocker (P-CAB) with potent acid suppression, but real-world evidence is limited. This study assesses symptom improvement and patient satisfaction with zastaprazan in patients with GERD.
Methods: This multicenter, prospective observational study enrolled adults diagnosed with GERD who received zastaprazan 20 mg daily for 4 weeks. Symptoms were assessed using the Reflux Disease Questionnaire (RDQ). The primary endpoint was the change in the mean GERD score of the RDQ. Secondary endpoints included the mean total RDQ score, patient satisfaction, compliance, and effectiveness stratified by prior medication use and diagnostic method.
Results: Among 5499 participants, the mean GERD score significantly decreased from 2.07 ± 1.12 to 0.44 ± 0.63 at week 4 (change: -1.63 ± 1.07, P < 0.0001). Symptom improvement was observed in treatment-naïve patients (n = 4906, -1.64 ± 1.08, P < 0.0001) and those previously treated with histamine-2 receptor antagonists, proton pump inhibitors, or P-CABs (n = 593, -1.60 ± 1.03, P < 0.0001). The switching group (within 2 days) also showed significant improvement (n = 304, -1.53 ± 1.05, P < 0.0001). Over 90% reported satisfaction, compliance was 93%, and only 2.25% required concomitant medications. Safety was excellent, with only 3 cases of mild adverse reactions (0.05%) and no serious events.
Conclusions: Zastaprazan was associated with clinically meaningful symptom improvement in GERD patients, regardless of prior medication history, including proton pump inhibitors or other P-CABs, with high patient satisfaction, and a favorable safety profile.
Related
- Effectiveness and safety of imeglimin in routine clinical practice among Indian patients with type 2 diabetes mellitus: a prospective, non-interventional, real-world observational study (INDI-TIMES 2.0)
- Perceived Simulation Design Quality, Educational Effectiveness, Satisfaction, and Self-Confidence in a Resource-Conscious Burn Care Simulation: A Multicentre Observational Study.
- A Poly‐L‐Lactic Acid Formulation for Nasolabial Fold Correction: Handling, Tolerability and Effectiveness in a Prospective Observational Study
- Real-world effectiveness and safety of enavogliflozin in patients with type 2 diabetes: A 24-week prospective multicenter observational study in Korea.
- Effectiveness of metformin as initial treatment on the metabolic profile of Saudi patients newly diagnosed with type 2 diabetes mellitus : A prospective observational study
BibTeX
@article{seo2026effectiveness,
title = {{Effectiveness and Patient Satisfaction With Zastaprazan in Real-World Practice: A Large-Scale Prospective Observational Study}},
author = {Seung In Seo and Kwang Hyun Ahn and Yong Sung Kim},
journal = {Journal of Neurogastroenterology and Motility},
year = {2026},
month = oct,
doi = {10.5056/jnm26017},
url = {https://doi.org/10.5056/jnm26017},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Effectiveness and Patient Satisfaction With Zastaprazan in Real-World Practice: A Large-Scale Prospective Observational Study
AU - Seung In Seo
AU - Kwang Hyun Ahn
AU - Yong Sung Kim
PY - 2026
DA - 2026/10/31
JO - Journal of Neurogastroenterology and Motility
DO - 10.5056/jnm26017
UR - https://doi.org/10.5056/jnm26017
AB - Background/Aims: Gastroesophageal reflux disease (GERD) remains a prevalent condition with unmet therapeutic needs. Zastaprazan is a novel potassium-competitive acid blocker (P-CAB) with potent acid suppression, but real-world evidence is limited. This study assesses symptom improvement and patient satisfaction with zastaprazan in patients with GERD. Methods: This multicenter, prospective observational study enrolled adults diagnosed with GERD who received zastaprazan 20 mg daily for 4 weeks. Symptoms were assessed using the Reflux Disease Questionnaire (RDQ). The primary endpoint was the change in the mean GERD score of the RDQ. Secondary endpoints included the mean total RDQ score, patient satisfaction, compliance, and effectiveness stratified by prior medication use and diagnostic method. Results: Among 5499 participants, the mean GERD score significantly decreased from 2.07 ± 1.12 to 0.44 ± 0.63 at week 4 (change: -1.63 ± 1.07, P < 0.0001). Symptom improvement was observed in treatment-naïve patients (n = 4906, -1.64 ± 1.08, P < 0.0001) and those previously treated with histamine-2 receptor antagonists, proton pump inhibitors, or P-CABs (n = 593, -1.60 ± 1.03, P < 0.0001). The switching group (within 2 days) also showed significant improvement (n = 304, -1.53 ± 1.05, P < 0.0001). Over 90% reported satisfaction, compliance was 93%, and only 2.25% required concomitant medications. Safety was excellent, with only 3 cases of mild adverse reactions (0.05%) and no serious events. Conclusions: Zastaprazan was associated with clinically meaningful symptom improvement in GERD patients, regardless of prior medication history, including proton pump inhibitors or other P-CABs, with high patient satisfaction, and a favorable safety profile.
SN - 2093-0879
SN - 2093-0887
ER -